CD80 and cancer: Programmed cell death 1 (PD1): programmed cell death 1 ligand 1 (PDL1), and cytotoxic T lymphocyte-associated protein 4 (CTLA4): B-lymphocyte activation antigen B7 (B7-1; also termed CD80) are the most extensively studied immune checkpoints for cancer immunotherapy.